Modified fragment of human growth hormone residues 176–191
PRODUCT PROFILE
AOD-9604
£32.49
AOD-9604 is modified fragment of human growth hormone residues 176–191. Researchers examine it in relation to whether a c-terminal gh fragment can influence lipid metabolism without full gh signalling.
Why it is distinct
A GH-derived metabolic fragment—not an incretin, amylin analogue or GH secretagogue.
- Evidence stageEarly human evidence
- AvailabilityAvailable · 10 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
10 in stock
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
AOD-9604 is modified fragment of human growth hormone residues 176–191. Researchers examine it in relation to whether a c-terminal gh fragment can influence lipid metabolism without full gh signalling.
Research focus+
Researchers study whether it can affect how fat is broken down without producing all the wider effects of full growth hormone. Human results have been limited and it remains experimental.
How the mechanism differs+
Designed to retain proposed lipolytic signalling from a GH fragment while limiting broader growth-promoting activity.
Evidence and limitations+
Small early human studies exist, but efficacy was not established sufficiently for medicine authorisation; much discussion exceeds the evidence.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can affect how fat is broken down without producing all the wider effects of full growth hormone. Human results have been limited and it remains experimental.
Designed to retain proposed lipolytic signalling from a GH fragment while limiting broader growth-promoting activity.
A GH-derived metabolic fragment—not an incretin, amylin analogue or GH secretagogue.
Small early human studies exist, but efficacy was not established sufficiently for medicine authorisation; much discussion exceeds the evidence.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Established
Tirzepatide
£79.0010 mgBatch file pendingDual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
UnavailableAsk about availability -
Clinical research
Cagrilintide
£64.005 mgBatch file pendingTargets amylin biology, making it mechanistically distinct from every incretin agonist in the category.
UnavailableAsk about availability -
Established
Semaglutide
£69.005 mgBatch file pendingA single-pathway GLP-1 comparator rather than a dual or triple incretin agonist.
UnavailableAsk about availability -
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket